Protagenic therapeutics to effect 1-for-14 reverse stock split

Measure taken to comply with nasdaq rule 5550(a)(2) regarding minimum bid price new york, ny / access newswire / april 29, 2025 / protagenic therapeutics, inc. (nasdaq:ptix) ("protagenic therapeutics" or the "company"), a leader in biopharmaceutical innovation, today announced that the company's board of directors has approved a 1-for-14 reverse stock split of the company's issued and outstanding common stock, par value $0.0001 per share (the "common stock") to be effective 12:01 a.m., eastern time, on may 5, 2025.
PTIX Ratings Summary
PTIX Quant Ranking